58th Competent Authorities for Medical Devices Meeting (CAMD) 15 – 17 April 2026

The Cyprus Presidency of the Council of the European Union organised the 58th meeting of the Competent Authorities for Medical Devices (CAMD) in Larnaka on 16–17 April 2026, with the participation of representatives of competent authorities from the Member States, with the aim of exchanging views and coordinating joint actions.

Opening the meeting, the Director of Medical and Public Health Services highlighted the importance of cooperation, trust, and alignment among competent authorities, setting the tone for constructive dialogue and collaborative efforts to address shared challenges across the European Union.

Participants reviewed the outcomes of the previous CAMD meeting in Copenhagen, ensuring continuity of work and building on the progress achieved in governance and regulatory coordination. An overview of the activities of the Cyprus Competent Authority for Medical Devices (CyMDA) was also presented, highlighting the importance of continuous collaboration and targeted actions to further strengthen the system.

The European Commission provided a comprehensive update on the Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), outlining ongoing reforms aimed at simplifying procedures, reducing administrative burden, and fostering innovation, while maintaining the highest standards of patient safety. Key developments include the gradual rollout of EUDAMED, new legislative measures, and the introduction of a more proportionate, risk-based regulatory approach.

Particular emphasis was placed by the Commission on key horizontal priorities, including digital transformation and artificial intelligence, the implementation of the Health Technology Assessment (HTA) Regulation, as well as the strengthening of market surveillance and standardisation, alongside highlighting issues related to cybersecurity and environmental sustainability. These initiatives enhance coherence with broader European Union policies and contribute significantly to strengthening a modern and resilient regulatory framework.

Significant progress was also recorded in joint actions under the EU4Health program. An update on the latest activities and deliverables of the Joint Action on Market Surveillance (JAMS 2.0) were shared along with the plans foreseen with the prospective-extension of the project (until April 2027). At the same time, an overview of the upcoming Joint Action (RASCO) was-provided.The objectives pursued are toprovide regulatory and scientific support to small and micro-enterprises, strengthening the

development and conformity assessment of innovative medical devices, as well as enhancing EU-level coordination on safety issues.
Key discussions focused on emerging regulatory challenges, particularly in the areas of Medical Device Software (MDSW) and in-house in vitro diagnostics (IVDs). It was recognised that new approaches, tools, and expertise are required to effectively address the complexities associated with digital technologies and to ensure a proportionate framework for accredited laboratories.

Breakout sessions further explored the future of the CAMD network, preparedness for the AI era, and the control of online sales and imported products. Participants expressed a preference for a strengthened and more coordinated network model that preserves the distinct identity of the medical devices sector while enhancing collaboration at EU level.

Discussions also highlighted the need to reinforce skills and resources related to artificial intelligence, as well as to improve cooperation with customs authorities and leverage digital tools, such as web crawling, to enhance market surveillance and consumer protection.

Looking ahead, Ireland will assume the next Presidency of the Council of the European Union. The next CAMD meetings are scheduled to take place in Dublin, with the Executive Group (CEG) meeting on September 2026.